Page last updated: 2024-09-04

atazanavir sulfate and Atherosclerosis

atazanavir sulfate has been researched along with Atherosclerosis in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Hatleberg, CI; Ryom, L; Sabin, C1
Ard, KL; Beckman, JA; Milian, J; Prenner, JC; Price, CN; Sax, PE; Solomon, DA; Wood, BR; Zuflacht, JP1
Bandera, A; Clerici, M; Fenizia, C; Giannattasio, C; Gori, A; Maloberti, A; Masetti, M; Muscatello, A; Sabbatini, F; Soria, A; Squillace, N; Trabattoni, D1
Beckman, JA; Goldfine, AB; Milian, J; Parmer, C; Zuflacht, JP1
Ando, A; Baumer, Y; Byron, MM; Chow, D; Kallianpur, KJ; Keating, S; Kohorn, L; Ndhlovu, L; Shikuma, C; Souza, S1
Ansart, S; Bellein, V; Bressollette, L; de Saint-Martin, L; Pasquier, E; Perfezou, P; Vallet, S1
Chen, L; Ding, H; Gurley, EC; Hu, W; Hylemon, PB; Jarujaron, S; Pandak, WM; Studer, E; Wang, JY; Zhou, H; Zou, T1

Reviews

1 review(s) available for atazanavir sulfate and Atherosclerosis

ArticleYear
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
    Expert opinion on drug safety, 2021, Volume: 20, Issue:11

    Topics: Animals; Atazanavir Sulfate; Atherosclerosis; Cardiovascular Diseases; Darunavir; Dyslipidemias; Heart Disease Risk Factors; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic

2021

Trials

2 trial(s) available for atazanavir sulfate and Atherosclerosis

ArticleYear
Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Biomarkers; Cross-Sectional Studies; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Viral Load

2017
Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.
    Acta diabetologica, 2015, Volume: 52, Issue:4

    Topics: Adult; Antioxidants; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Blood Pressure; Cardiovascular System; Cholesterol, LDL; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Vasodilation

2015

Other Studies

4 other study(ies) available for atazanavir sulfate and Atherosclerosis

ArticleYear
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Endothelial Cells; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Lymphocyte Activation; Male; Prospective Studies; Pulse Wave Analysis; Random Allocation; Ritonavir

2018
Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin.
    AIDS (London, England), 2016, Feb-20, Volume: 30, Issue:4

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Carotid Intima-Media Thickness; Female; HIV Infections; Humans; Male; Retrospective Studies

2016
Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
    AIDS (London, England), 2010, Nov-27, Volume: 24, Issue:18

    Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Cohort Studies; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Tunica Intima; Tunica Media

2010
HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.
    Atherosclerosis, 2007, Volume: 195, Issue:1

    Topics: Animals; Antigens, Surface; Atazanavir Sulfate; Atherosclerosis; ELAV Proteins; ELAV-Like Protein 1; Endoplasmic Reticulum; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Interleukin-6; Lentivirus; Macrophages; Mice; Oligopeptides; Pyridines; Risk Factors; RNA-Binding Proteins; Tumor Necrosis Factor-alpha

2007